Alcohol use disorders: clinical and biological predictors of treatment outcome

The Research Institute, McGill University Health Centre (Canada)0 个研究点目标入组 389 人开始时间: 2005年9月26日最近更新: 2015年1月13日

试验速览

暂无简介。

•1. Women and men between 18 and 65 years of age
•2. Who request treatment at the Addictions Unit
•3. Who suffer from alcohol abuse or dependence (as per DSM-IV diagnostic criteria)
•4. Who can be contacted reliably
•5. Who have signed the consent form (as approved by the local Clinical Trials Committee)

•1. If they currently suffer from another substance dependence, excluding nicotine (as per DSM-IV diagnostic criteria)
•2. If they are likely to suffer severe alcohol withdrawal symptoms necessitating hospitalisation (as per American Society of Addiction Medicine guidelines for inpatient alcohol detoxification)
•3. If they currently suffer from schizophrenia, schizoaffective disorder, or bipolar disorder
•4. If they are currently experiencing psychotic symptoms or suicidal ideation (as determined by clinical interviews by the RA and an Addictions Unit psychiatrist)
•5. If they are taking or have taken a serotonergic agent in the two weeks prior to enrolment in the study (four weeks in the case of fluoxetine) e.g. any antidepressant medication, including SSRIs, tricyclic antidepressants, MAO inhibitors, and St. John?s Wort; any mood stabilizer, including carbamazepine, lamotrigine, lithium, and valproate; any antipsychotic medication, including conventional and novel antipsychotics etc.
•6. If a female patient is pregnant or breast-feeding - NB women of childbearing potential must be practicing an effective method of birth control while participating in this study, and must agree not to become pregnant during their participation in this study
•7. If they have a history of serious adverse reactions or intolerance of selective serotonin reuptake inhibitors (SSRIs)

发起方

The Research Institute, McGill University Health Centre (Canada)